Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06249165 · ClinicalTrials.gov registry record · Phase 4
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
A Phase 4 study of Atherosclerotic Cardiovascular Disease, sponsored by Duke University.
- Active
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06249165: Active Phase 4 study of Atherosclerotic Cardiovascular Disease, sponsored by Duke University.
NCT06249165 is a Phase 4 study of Atherosclerotic Cardiovascular Disease that is active but no longer recruiting, run by Duke University. The registered enrollment target is 130 participants, below the 7,562-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06249165, a Phase 4 study of Atherosclerotic Cardiovascular Disease, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
Primary Outcome
Achieving LDL-C targets (LDL-C \< 70 mg/dL for ASCVD participants or LDL-C \< 100 for ASCVD risk equivalent participants) (yes/no)
Conditions Studied
Interventions
- DRUG Inclisiran
Study Locations (20)
North Carolina
- University of North Carolina - Chapel Hill
- Duke University Medical Center - Durham
- Wake Forest University - Winston-Salem
California
- Univ. of California - Irvine - Orange
- San Francisco General Hospital - San Francisco
Georgia
- Emory University - Atlanta
- Wellstar Paulding - Hiram
Maryland
- JHU - Suburban Hospital - Bethesda
- Johns Hopkins - Columbia
Missouri
- University of Missouri - Columbia
- Washington University - St Louis
Alabama
- Univ. of Alabama - Birmingham - Birmingham
Illinois
- Rush University - Chicago
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2027-02 |
| Phase | Phase 4 |
What the registry record for NCT06249165 still lists
NCT06249165 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 7,562-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Inclisiran is the first listed.
NCT06249165 names 20 study sites across 14 states, led by North Carolina, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06249165 about?
NCT06249165 is a clinical study titled "VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease". VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to ...
What is the current status of trial NCT06249165?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2024-12-16. Estimated completion is 2027-02.
What conditions does trial NCT06249165 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06249165?
The interventions under investigation include: Inclisiran (DRUG).
Who is sponsoring clinical trial NCT06249165?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06249165 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06249165's enrollment target sits among peer trials
130 17th of 21 higher than 5 of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
COMPLETED · Phase 4
-
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
RECRUITING · NA
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
-
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI